-
公开(公告)号：US09555041B2
公开(公告)日：2017-01-31
申请号：US14804407
申请日：2015-07-21
申请人： Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
发明人： Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
IPC分类号： A61K31/5377 , A61K31/4155 , A61K31/454 , A61K31/4196 , A61K31/4192 , A61K31/497 , A61K31/505 , A61K31/426 , A61K31/50 , C07C281/02 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/24 , C07D239/36 , C07D239/54 , C07D249/04 , C07D249/10 , C07D249/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D263/34 , C07D263/38 , C07D277/56 , C07D401/04 , C07D403/04 , C07D403/06 , C07D413/04 , C07D471/04 , C07D239/28 , C07D239/34 , C07D239/52 , C07D401/06 , A61K31/41 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/437
CPC分类号： C07D471/04 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , C07C281/02 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/14 , C07D237/24 , C07D239/28 , C07D239/34 , C07D239/36 , C07D239/52 , C07D239/54 , C07D249/04 , C07D249/10 , C07D249/12 , C07D249/18 , C07D257/04 , C07D261/12 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/38 , C07D277/34 , C07D277/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/04 , Y02P20/55
摘要： In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中R 1 -R 6，a，b和X如说明书中所定义，或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
32.发明授权公开(公告)号：US09550783B2
公开(公告)日：2017-01-24
申请号：US14280972
申请日：2014-05-19
发明人： Jiacheng Zhou , Ashoke Bhattacharjee , Shili Chen , Yi Chen , Jay J. Farmer , Joel A. Goldberg , Roger Hanselmann , Rongliang Lou , Alia Orbin , Adegboyega K. Oyelere , Joseph M. Salvino , Dane M. Springer , Jennifer Tran , Deping Wang , Yusheng Wu
IPC分类号： A01N43/80 , C07D261/04 , C07D487/04 , C07D263/20 , C07D263/32 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14 , C07D453/02 , C07D473/00 , C07D263/24 , C07D473/34 , C07D263/26 , C07D471/04
CPC分类号： C07D487/04 , C07D263/20 , C07D263/24 , C07D263/26 , C07D263/32 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14 , C07D453/02 , C07D471/04 , C07D473/00 , C07D473/34
摘要： The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.
摘要翻译： 本发明一般涉及抗感染，抗增殖，抗炎和促动力的领域。 更具体地，本发明涉及具有联芳基部分和至少一个可用作这种试剂的杂环部分的化合物族。
-
33.发明授权Use of Burkholderia formulations, compositions and compounds to modulate crop yield and/or corn rootworm infestation 有权使用伯克霍尔德氏菌配方，组合物和化合物来调节作物产量和/或玉米根虫侵染公开(公告)号：US09526251B2
公开(公告)日：2016-12-27
申请号：US14548824
申请日：2014-11-20
发明人： Ratnakar Asolkar , Marja Koivunen , Pamela Marrone , Ana Lucia Cordova-Kreylos , Huazhang Huang
IPC分类号： A01N63/00 , A01N63/02 , C07D309/14 , C07D407/06 , C07D413/04 , C07D413/06 , C07D263/32 , C07D263/34 , C07D493/10 , C07D498/14 , C07D513/04
CPC分类号： A01N63/02 , A01N25/12 , A01N25/14 , A01N63/00 , C07D263/32 , C07D263/34 , C07D309/14 , C07D407/06 , C07D413/04 , C07D413/06 , C07D493/10 , C07D498/14 , C07D513/04 , A01N25/00
摘要： Provided is the use of or compositions or formulations comprising Burkholderia species, filtrate, supernatant, extract, pesticidally active compound or metabolite derived therefrom as an insecticide, particularly against infestation of Corn Rootworm larvae, and/or as crop yield enhancer.
摘要翻译： 提供了包含伯克霍尔德杆菌属物种，滤液，上清液，提取物，杀虫活性化合物或其衍生的代谢物作为杀虫剂，特别是抗玉米根虫幼虫侵染的作物或/或作为作物产量增强剂的组合物或制剂。
-
公开(公告)号：US09522914B2
公开(公告)日：2016-12-20
申请号：US14353447
申请日：2012-10-25
发明人： Mitsukane Yoshinaga , Takeshi Kuwada , Naoki Miyakoshi , Tomoko Ishizaka , Daisuke Wakasugi , Shin-ichi Shirokawa , Nobutaka Hattori , Youichi Shimazaki
IPC分类号： C07D491/107 , C07D471/08 , C07D403/10 , C07D498/08 , C07D233/64 , C07D401/10 , C07D231/12 , C07D233/70 , C07D233/90 , C07D401/04 , C07D403/04 , C07D403/06 , C07D413/10 , C07D249/08 , C07D451/06 , C07D249/10 , C07D249/12 , C07D263/32 , C07D277/20 , C07D277/30 , C07D207/444
CPC分类号： C07D471/08 , C07D207/444 , C07D231/12 , C07D233/64 , C07D233/70 , C07D233/90 , C07D249/08 , C07D249/10 , C07D249/12 , C07D263/32 , C07D277/20 , C07D277/30 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D413/10 , C07D451/06 , C07D491/107 , C07D498/08
摘要： The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:
-
公开(公告)号：US09504675B2
公开(公告)日：2016-11-29
申请号：US13983369
申请日：2012-02-03
申请人： Dale L. Boger
发明人： Dale L. Boger
IPC分类号： C07D413/04 , A61K31/421 , A61K45/06 , C07D271/10 , A61K31/4439 , A61K31/4245 , C07D263/32 , C07D263/34
CPC分类号： A61K31/421 , A61K31/4245 , A61K31/4439 , A61K45/06 , C07D263/32 , C07D263/34 , C07D271/10 , C07D413/04
摘要： Compounds are disclosed that are effective in inhibition of fatty acid amide hydrolase, an enzyme responsible for catabolism of endogenous cannabinoids such as anandamide. The compounds are useful as analgesic compounds and as sleep-inducing compounds, that can be orally administered, and that can have a relatively long duration of effect. Methods of preparation of the compounds are also provided. The compounds are conformationally constrained analogs of heterocyclylketones such as oxazolylketones.
摘要翻译： 公开了有效抑制脂肪酸酰胺水解酶的化合物，脂肪酸酰胺水解酶是负责内源性大麻素例如anandamide分解代谢的酶。 这些化合物可用作止痛化合物和作为睡眠诱导化合物，其可以口服给药，并且可以具有相对较长的作用持续时间。 还提供了化合物的制备方法。 化合物是杂环基酮的构象约束类似物，例如恶唑基酮。
-
36.发明申请公开(公告)号：US20160340322A1
公开(公告)日：2016-11-24
申请号：US15105361
申请日：2014-12-17
发明人： Michiaki ADACHI , Masataka MINAMI , Jun EGI , Yuichi HIRAI , Toshimasa IWAMOTO , Yusuke SHINTANI , Takuya OKADA , Daiki TAKAHASHI
IPC分类号： C07D253/075 , C07D409/14 , C07D471/04 , C07D413/14 , C07D417/14 , C07D405/14 , C07D401/14 , C07D409/06 , C07D417/06
CPC分类号： C07D253/075 , C07D211/38 , C07D211/42 , C07D211/96 , C07D253/06 , C07D253/07 , C07D263/32 , C07D333/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/14 , C07D471/04
摘要： Disclosed is a novel triazinone compound with an inhibitory activity on a T-type voltage-dependent calcium channel, and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. A novel triazinone compound of Formula (I), wherein each substituent in the formula is defined in detail in the description, R4 means a hydrogen atom, or a C1-6 alkoxy group, etc., L1 and L2 each independently mean a single bond, or NR2, etc., L3 means a C1-6 alkylene group, etc., A means a C6-14 aryl group or a 5 to 10-membered heteroaryl group which may be substituted, B means a C3-11 cycloalkylene group, etc., D means a C6-14 aryl amino group or a 5 to 10-membered heteroaryl group which may be substituted, etc., a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt.
摘要翻译： 本发明的目的是提供对T型电压依赖性钙通道具有抑制活性的新颖的三嗪酮化合物，特别可用于预防或治疗疼痛，慢性肾脏疾病和心房颤动。 式（I）的新颖的三嗪酮化合物：其中式中的每个取代基在说明书中详细定义，R 4表示氢原子或C 1-6烷氧基等，L 1和L 2各自独立地 表示单键或NR 2等，L 3表示C 1-6亚烷基等，A表示可以被取代的C 6-14芳基或5〜10元杂芳基，B 是指C 3-11亚环烷基等，D表示C 6-14芳基氨基或可被取代的5至10元杂芳基等，化合物的互变异构体，药学上可接受的盐 化合物或化合物的溶剂合物，互变异构体或药学上可接受的盐。
-
公开(公告)号：US09487495B2
公开(公告)日：2016-11-08
申请号：US14369982
申请日：2013-01-07
发明人： Justin S. Cisar , Cheryl A. Grice , Todd K. Jones , Micah J. Niphakis , Jae Won Chang , Kenneth M. Lum , Benjamin F. Cravatt
IPC分类号： C07D295/205 , C07D317/46 , C07D317/58 , C07D401/06 , C07D403/06 , C07D407/06 , C07D413/06 , A61K31/495 , A61K31/496 , C07D295/26 , C07D405/14 , C07D215/42 , C07D213/40 , C07C271/12 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D471/04 , C07D471/10 , C07D261/08 , C07D487/04 , C07D263/32 , C07D205/04 , C07D491/107 , C07D207/14 , C07D271/06 , C07D307/79 , C07D213/55 , C07D401/04 , C07C271/10 , C07D207/09
CPC分类号： C07D295/205 , C07C271/10 , C07C271/12 , C07D205/04 , C07D207/09 , C07D207/14 , C07D213/38 , C07D213/40 , C07D213/55 , C07D215/42 , C07D215/46 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D295/26 , C07D307/79 , C07D317/46 , C07D317/58 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/14 , C07D407/06 , C07D413/06 , C07D413/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： This disclosure provides compounds having the structure: wherein L3, R7, Rd and p are defined herein, which are modulators of MAGL and/or ABHD6. Further provided is the use of these compounds as medicinal agents, processes for their preparation, and pharmaceutical compositions that include the disclosed compounds. The disclosure also provides a method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
摘要翻译： 本公开提供了可以是MAGL和/或ABHD6的调节剂的化合物和组合物及其作为药物的用途，其制备方法和包含公开的化合物作为至少一种活性剂的药物组合物。 本公开还提供了治疗有需要的患者的方法，其中患者患有诸如疼痛，实体瘤癌症和/或肥胖的适应症，其包括施用所公开的化合物或组合物。
-
公开(公告)号：US20160310471A1
公开(公告)日：2016-10-27
申请号：US14997364
申请日：2016-01-15
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Thomas Fowler , Andrew Novak , Premji Meghani , Enugurthi Brahmachary , Adam Richard Yeager
IPC分类号： A61K31/4245 , A61K31/4439 , A61K31/4725
CPC分类号： A61K31/4245 , A61K9/0019 , A61K9/0095 , A61K31/155 , A61K31/235 , A61K31/341 , A61K31/4406 , A61K31/4439 , A61K31/4465 , A61K31/4725 , A61K31/495 , A61K31/505 , A61K31/5375 , A61K31/54 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07C229/14 , C07C233/47 , C07C233/51 , C07C233/81 , C07C233/83 , C07C235/12 , C07C235/38 , C07C235/48 , C07C237/22 , C07C237/36 , C07C237/42 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/48 , C07C317/28 , C07C317/44 , C07C323/62 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/267 , C07D209/08 , C07D211/14 , C07D211/34 , C07D211/62 , C07D213/55 , C07D213/65 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D215/48 , C07D217/02 , C07D231/12 , C07D233/60 , C07D235/06 , C07D235/12 , C07D235/18 , C07D239/26 , C07D239/28 , C07D239/74 , C07D239/91 , C07D241/42 , C07D241/44 , C07D249/08 , C07D257/04 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/48 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/107 , C07D277/30 , C07D277/56 , C07D277/66 , C07D279/12 , C07D295/15 , C07D295/155 , C07D295/205 , C07D295/24 , C07D307/24 , C07D307/54 , C07D307/68 , C07D307/79 , C07D309/06 , C07D309/08 , C07D311/16 , C07D317/68 , C07D333/38 , C07D413/04 , C07D413/12 , C07D417/12 , C08B37/0015 , C08L5/16 , A61K2300/00
摘要： Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.
摘要翻译： 结合胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法，其治疗和/或预防用途的方法及其在体外稳定GLP-1受体中用于GLP- 1受体。 某些化合物自身或存在受体配体如GIP（1-42），PTH可能具有作为胰高血糖素受体，GIP受体，GLP-1和GLP-2受体以及PTH受体的调节剂或增效剂的活性 （1-34），胰高血糖素（1-29），GLP-2（1-33），GLP-1（7-36），GLP-1（9-36），胃泌酸调节蛋白和毒蜥外泌肽变体。
-
公开(公告)号：US09458181B2
公开(公告)日：2016-10-04
申请号：US14506760
申请日：2014-10-06
发明人： Shawn Stachel , Daniel V. Paone , Jing Li , Kausik Nanda
IPC分类号： A61K31/421 , C07D263/32 , C07D263/34 , C07D277/30 , C07D413/04 , C07D413/10 , C07D417/10 , C07D417/14 , C07D495/08 , C07F7/08 , A61K31/695 , A61K31/422 , A61K31/547 , A61K31/541 , A61K31/5377 , A61K31/496 , C07D513/08 , A61K31/427 , A61K45/06 , C07D413/12
CPC分类号： C07F7/0807 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/547 , A61K31/695 , A61K45/06 , C07D263/32 , C07D263/34 , C07D277/30 , C07D413/04 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D495/08 , C07D513/08
摘要： This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
-
40.发明申请公开(公告)号：US20160264566A1
公开(公告)日：2016-09-15
申请号：US15067124
申请日：2016-03-10
发明人： William F. DeGrado , Dean Sheppard , Hyunil Jo , Nilgun Isik Reed , Youzhi Tang , Joel McIntosh
IPC分类号： C07D417/12 , C07D249/06 , C07C279/14 , C07D471/04 , C07D233/50 , C07D217/24 , C07D263/32 , C07D277/30 , C07D401/12 , C07D239/14 , C07D413/12 , C07D403/12 , C07D271/02 , C07D285/04 , G01N33/68 , C07D213/74
CPC分类号： C07D417/12 , C07C279/14 , C07D213/74 , C07D217/24 , C07D233/50 , C07D239/14 , C07D249/06 , C07D263/32 , C07D271/02 , C07D277/30 , C07D285/04 , C07D401/12 , C07D403/12 , C07D413/12 , C07D471/04 , G01N33/573 , G01N33/6863 , G01N2333/7055
摘要： Provided herein, inter alia, are methods and compositions for inhibiting αvβ1 integrin and for treating fibrosis.
摘要翻译： 本文提供了用于抑制αvβ1整联蛋白和治疗纤维化的方法和组合物。
-
-
-
-
-
-
-
-
-
搜索结果
1895 条记录 (耗时 0.076 秒)
